[144] CNO Financial Group, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for proposed sale of CNO Financial Group, Inc. securities. The filing reports an intended sale of 3,457 common shares with an aggregate market value of $130,845.38. The shares represent part of outstanding common stock of 96,931,934 and the approximate proposed sale date is 08/15/2025 on the NYSE. The 3,457 shares were acquired from the issuer as restricted stock (1,985 shares, 03/25/2024) and performance shares (1,472 shares, 02/15/2024).

Recent sales by the same person are disclosed: Jeanne Linnenbringer sold a total of 11,282 common shares on 08/13/2025 and 08/14/2025 across four trades, generating gross proceeds of $524,457.40 in aggregate as reported. The filer affirms no undisclosed material adverse information and includes standard Rule 144 and Rule 10b5-1 representations.

Positive

• Disclosure completeness: Acquisition dates, share types, quantities, recent sales, and gross proceeds are provided.
• Compliance representation: The filer affirms no undisclosed material adverse information and references Rule 10b5-1 where applicable.

Negative

• No 10b5-1 plan date disclosed: The form references Rule 10b5-1 but does not provide a plan adoption or instruction date.
• Limited issuer identification: Issuer name and some filer contact fields are not populated in the provided content block.

Insights

Securities/Equity Analyst

TL;DR: Routine insider sale notice; small position relative to total shares outstanding, unlikely to be market-moving.

This Form 144 documents a proposed disposition of 3,457 common shares valued at $130,845.38, representing a very small fraction of the issuer's ~96.9 million shares outstanding. The shares were issued as restricted and performance awards in early 2024 and are now cleared for sale under Rule 144. Recent reported sales by the same individual total 11,282 shares with disclosed gross proceeds of $524,457.40. From an equity perspective, these disclosures are standard insider liquidity events and do not by themselves indicate operational or financial stress at the company.

Compliance / Corporate Governance Expert

TL;DR: Filing appears to follow Rule 144 disclosure requirements; includes required acquisition and recent-sale details and the insider certification.

The form lists acquisition dates, share types (restricted stock and performance shares), and recent sales, meeting Rule 144 transparency expectations. The signer represents no undisclosed material adverse information and notes potential reliance on a trading plan or instruction under Rule 10b5-1, though no plan adoption date is provided. For governance review, the filing supplies material transactional data but does not include any additional disclosure about trading plan adoption dates or reliance which would be relevant if a 10b5-1 defense is claimed.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3457	130845.38	96931934	08/15/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/25/2024	Restricted Stock	ISSUER			1985	03/25/2024	Not Applicable
Common	02/15/2024	Performance Shares	ISSUER			1472	02/15/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JEANNE LINNENBRINGER 11299 Illinois Street Carmel IN 46032	Common	08/14/2025	3384	128522.29
JEANNE LINNENBRINGER 11299 Illinois Street Carmel IN 46032	Common	08/14/2025	1478	56133.55
JEANNE LINNENBRINGER 11299 Illinois Street Carmel IN 46032	Common	08/13/2025	4420	167782.76
JEANNE LINNENBRINGER 11299 Illinois Street Carmel IN 46032	Common	08/13/2025	2000	75919.80

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does this Form 144 for CNO (CNO) report?

It reports a proposed sale of 3,457 CNO common shares valued at $130,845.38, with an approximate sale date of 08/15/2025 on the NYSE.

Who previously sold shares and how many were sold recently?

The filing shows Jeanne Linnenbringer sold four tranches on 08/13/2025 and 08/14/2025 totaling 11,282 shares for gross proceeds of $524,457.40.

How were the 3,457 shares acquired?

They were acquired from the issuer as restricted stock (1,985 shares on 03/25/2024) and performance shares (1,472 shares on 02/15/2024).

Does the filing indicate any undisclosed material adverse information?

The signer represents by signature that they do not know any material adverse information that has not been publicly disclosed.

Is there an indicated reliance on a 10b5-1 trading plan?

The form references Rule 10b5-1 and space for a plan adoption date, but no plan adoption date or instruction date is provided in the content.